The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The activity is determined by the dose-dependant induction of IL-6 in NIH 3T3 cells and is typically 35-50 ng/mL. This corresponds to an expected specific activity of 2.8 x 104 units/mg.
< 0.050 Eu/µg
>95% by SDS-PAGE .
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute with sterile water to 0.1 mg/mL. Centrifuge vial before opening. Suspend the product by gently pipetting down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. Dilute to working aliquots in a 0.1% BSA solution.
Cytokine ML 1
Mutant IL 17F
Ligand for IL17RA and IL17RC (PubMed:17911633). The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC (PubMed:18684971). Involved in stimulating the production of other cytokines such as IL6, IL8 and CSF2, and in regulation of cartilage matrix turnover (PubMed:11591732, PubMed:11591768, PubMed:11574464). Also involved in stimulating the proliferation of peripheral blood mononuclear cells and T-cells and in inhibition of angiogenesis (PubMed:11591732). Plays a role in the induction of neutrophilia in the lungs and in the exacerbation of antigen-induced pulmonary allergic inflammation.
Expressed in activated, but not resting, CD4+ T-cells and activated monocytes.